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Summary 
Transforming  growth  factor 131  null  mice  (TGF-131 -/-)  suffer from multifocal inflammation 
and die by 3-4 wk of age. In these mice, levels of nitric oxide (NO) reaction products in serum 
are elevated approximately fourfold over levels in controls,  peaking at  15-17  d  of life. Short- 
term treatment of TGF-131 -/-  mice with NG-monomethyl-L-arginine suppressed this elevated 
production  of NO.  Expression  of inducible  NO  synthase  (iNOS)  mR.NA  and protein  is in- 
creased in the kidney and heart ofTGF-131 -/-  mice. These findings demonstrate that TGF-131 
negatively regulates iNOS expression in vivo, as had been inferred from mechanistic studies on 
the control ofiNOS  expression by TGF-131 in vitro. 
T 
he  three  mammalian  isoforms  of TGF-13  mediate  a 
wide  array of physiological  processes  (1).  In addition 
to  their functions  in  development,  cell  cycle  control,  and 
wound  healing,  the  TGF-13s regulate  the function  of cells 
involved  in  the  immune  response  to  antigens,  mitogens, 
and pathogens  (2).  Among the immunomodulatory  effects 
attributed to the TGF-13s is the suppression of the produc- 
tion  of nitrogen  free radicals by macrophages in  vitro  (3). 
Nitric  oxide  (NO)  and  its  derived  nitrogen  free  radicals 
have  been  the  subject  of much  investigation,  owing  to 
their pleiotropic  effects (4). An enzyme inducible  by cyto- 
kines  and  microbial  products  present  in  many  cell  types 
(iNOS;  NOS type II) produces large quantities  of NO  (4). 
The cytotoxic or cytostatic effects of high levels of NO  are 
beneficial  during  infection  but  can  damage  host  tissue 
when unchecked (4). Accordingly, suppression of NO pro- 
duction by exogenously administered TGF-131 can have both 
deleterious and beneficial effects in different contexts (5). 
To  discern  whether  endogenous  TGF-131  can  control 
the expression of iNOS in vivo, we made use of the TGF- 
131  null  (TGF-131 -/-)  mouse  (6).  In contrast with  normal 
(TGF-131 +/+)  or  heterozygous  (TGF-131 +/-)  litterrnates, 
these mice develop multifocal inflammation and die after a 
wasting syndrome (6). TGF-131-/- mice exhibit high levels 
of circulating autoantibodies  (7) as well as increased expres- 
sion of MHC  class  I and II in the absence of increased ex- 
pression  of IFN-~/  (8),  suggesting that TGF-131  may be an 
active  repressor  of inflammation  even  in  the  absence  of 
proinflammatory stimuli.  For these  reasons,  and  owing  to 
the multiple regulatory effects of TGF-131  on NO  produc- 
tion in vitro (5), we examined whether production  of NO 
is dysregulated in TGF-131 -/-  mice. 
Materials  and Methods 
TGF-~I-/-Mice.  TGF-131 -/- mice were derived as described 
previously (6) and maintained in a specific  pathogen-free animal 
room. By routine screening of the animal colony, the mice were 
determined  not  to be infected with  any identifiable pathogens 1 
(data not shown). TGF-131-/- mice were identified by expressing 
the  null  allele  and  not  the  normal allele.  Genotyping was per- 
formed by PCR. from tail preparations  as described previously (8, 9). 
Treatment Protocols.  Mice were injected intraperitoneally with 
Ng-monomethyl-L-arginine  (L-NMA;  50-400  mg/kg;  Sigma 
Chemical Co., St. Louis, MO), NG-nitro-L-arginine methyl ester 
(r-NAME;  50  mg/kg;  Sigma),  or aminoguanidine  (50  mg/kg; 
Sigma). All injected solutions were diluted in sterile PBS and ster- 
ile filtered before injection. 
Preparation of Serum.  Mice were killed by asphyxiation in CO  2, 
and  blood  was  collected  in  microcentrifuge  tubes  after cardiac 
puncture.  Serum was obtained after centrifugation of coagulated 
blood and stored at -70~ 
Quantitation of N02 and NO~ in Serum.  Serum NO ~- and NO 3 
were assayed by reduction of NO2  to NO~  on Cd filings as de- 
scribed elsewhere (10). The samples were then assayed for NO2 
1Mice were screened routinely for the following pathogens: murine hep- 
atitis virus, pneumonia virus of mice, polioencephalomyelitis virus, lym- 
phocytic choriomeningitis virus, mouse cytomegalovirus, reovirus type 3, 
ectromelia virus, and mouse polyoma virus, as well as several types ofparo- 
virus, ectoparasites, and endoparasites. 
2337  j. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/96/05/2337/06  $2.00 
Volume 183  May 1996  2337-2342 content by the  Griess assay as described  elsewhere  (3,  11). The 
NO2  +  NO~ content of selected serum samples was verified by 
a modification of the nitrate reductase method (12). 
Preparation of Homogenates.  Organs were removed from mice 
by dissection and frozen at -70~  resuspended in 500 p~l ofson- 
ication buffer (40 mM Tris, pH 8.0, containing 5 p~g/ml  pepsta- 
tin A, 5 p,g/ml aprotinin, and 500 ~M AEBSF [ICN Biomedicals 
Inc.,  Costa  Mesa,  CA]),  and homogenized with  a  Kinematica 
electrical homogenizer (Brinkmann Instruments, Westbury, NY). 
The homogenates were centrifuged at room temperature, and the 
supernatant was stored at -70~ 
Northern Analysis.  Tissues were homogenized in GTC buffer 
(4.0  M  guanidine thiocyanate, 50  mM  Tris,  pH  7.0,  10  mM 
EDTA, 2% [wt/vol] sarkosyl, 1% [vol/vol] antifoam A  [Sigma]) 
purified by the CsC1 method as described previously (8, 9). 15 ~g 
of total RNA was electrophoresed  and blotted by standard meth- 
ods (13). Northern blotting was carried out according to the pro- 
cedure of Church and Gilbert (14) with the HinclI-EcoiLI frag- 
ment of the iNOS cDNA (15) and the 675-bp region within the 
TGF-[31  precursor cDNA starting  at the ATG initiation codon 
(16). After hybridization, the filters were exposed to a Phosphor- 
Imager (Molecular Dynamics, Inc., Sunnyvale, CA). 
Anti-iNOS Antibodies.  For immunocytochemical  detection of 
iNOS, we used  a rabbit polyclonal antiserum raised against the 
carboxy terminal EEPKATILL peptide of mouse iNOS coupled 
to  thyroglobulin as  a  Carrier by  use  of sulfo-MBS  chemistry 
(Pierce Chem. Co., ILockford, IL) (17). For irnmunoblotting,  we 
used a mouse mAb raised against a fragment of mouse iNOS from 
amino acids 961-1144 (Transduction Laboratories, Lexington, KY). 
SDS-PAGE  and Immunobtotting.  150--250  I~g of each homo- 
genate  was  separated  on  precast  4-20%  polyacrylamide  gels 
(NOVEX, Encinitas, CA) along with prestained mol wt standards 
(Amersham  Corp., Arlington Heights,  IL). As a positive  control 
for mouse iNOS, RAW 264.7 cells (American Type Culture Col- 
lection, ILockville, MD) were stimulated with IFN-~/(100 U/ml; 
GIBCO BILL, Gaithersburg,  MD) and LPS (200 ng/ml; prepared 
by phenol extraction from Escherichia coli Ol1:5; List Biological 
Laboratories,  Inc.,  Campbell, CA)  as  described  elsewhere  (18). 
The separated  proteins were immunoblotted by standard  meth- 
ods. In brief, membranes were blocked with 5% nonfat dry milk 
and incubated with a 1 : 5,000 dilution in 5% nonfat dry milk of 
anti-iNOS. Secondary antibody was a goat anti-mouse IgG cou- 
pled to HILP (Kirkegaard and Perry Laboratories,  Gaithersburg, 
MD). The membranes were visualized by enhanced chemilumi- 
nescence (Amersham). 
Histopathology  and Immunohistochemistry.  Tissues  were  fixed 
in 10% buffered formalin and embedded in paraffin. 5-lxm sec- 
tions were stained with hematoxylin-eosin and analyzed for his- 
topathology.  Tissue  sections  were  deparaffinized  at  65~  fol- 
lowed by incubation in xylene and ethanol. After  endogenous 
peroxidase  activity was blocked in HzO2-methanol, and nonspe- 
cific binding in 5% BSA, 1% normal goat serum was carried out, 
sections were incubated overnight at 4~  with anti-iNOS at a di- 
lution of 1 : 1,000.  Control for  specificity  of iNOS was normal 
rabbit serum. The adherent antibodies were reacted with biotiny- 
lated  goat  anti-rabbit or horse  anti-mouse secondary antibodies 
followed by HILP  conjugated to streptavidin (Vector  Laborato- 
ries,  Burlingame, CA).  These  complexes  were  visualized  with 
3,Y-diaminobenzidine  (Sigma) as a chromagen and CuSO  4 as an en- 
hancer. Sections were then counterstained with Meyers hematox- 
ylin and coverslipped.  The stained sections were imaged digitally. 
Data Analysis.  Data  are  presented  as  mean  +  SEM  unless 
stated  otherwise  and were  analyzed  for significance  by the  un- 
paired one-tailed Student's t-test. 
Results and Discussion 
The  experiments described herein were  carried out on 
TGF-131  -/-  mice obtained sequentially, owing to the low 
frequency of TGF-I31  -/-  mice in most litters (6,  19). We 
first looked for evidence of increased systemic production 
of NO, by assaying for NO2  and NO3, the predominant 
reaction products of NO  found in serum (4).  We also di- 
vided TGF-[31 +/+  and TGF-131 -/-  mice into cohorts  of 
equal age between 10 and 28 d to relate the age of the mice 
to  serum NO~  and NO3  content as  an indicator of sys- 
temic NO production. Serum levels of NO~ and NO3  of 
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Figure 1.  TGF-[31  -/- mice exhibit increased levels 
of NO2  and NO 3  in their sera as  compared with 
TGF-[31  +/+  mice, peaking between days 15 and 17. 
TGF-[~I  +/+  mice (open squares) or TGF-~I  -/- mice 
~qlled triangles) were killed upon reaching the indicated 
ages, and their serum levels of NOT  and NO 3 were 
determined. Values represent mean +  SEM of serum 
samples from 3-5 mice at each time point. Asterisk, P 
<0.05 when compared with TGF-[31+/+  mice. 
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tween  days  14  and  17  (Fig.  1;  P  <0.05  vs.  TGF-131 +/+ 
mice), '~1  wk before death and concomitant with the on- 
set of severe wasting (6,  19). 
Thus,  the  lack  of a  functional  TGF-[31  gene  product, 
with unaffected expression  of TGF-[32 and TGF-[33  (A.B. 
Roberts,  unpublished  observations),  is  associated  with  a 
fourfold  elevation  of NO2  and  NO3  in  serum  (Fig.  1). 
This  spontaneously  elevated  systemic  NO  production  is 
quite substantial: although all mice were free from infection 
(data not shown),  the serum levels of NO~  and NO3  ob- 
served in TGF-[31-/- mice are comparable to those of  mice 
injected with  C. parvum  (20) or staphylococcal enterotoxin 
B  (21).  The increase in systemic NO  production in TGF- 
[31 -/-  mice is greatest approximately at the time of wean- 
ing  (Fig.  1),  suggesting an  association  with  decreased  ma- 
ternally transferred TGF-[31  (9). 
Systemic NO  production in TGF-[31+/+ mice was rela- 
tively constant over 10-28  d  of age, though some fluctua- 
tion was observed (Fig.  1, open squares).  There was a signif- 
icant drop in the NO2  plus NO3  content in the serum of 
TGF-[31 -/-  mice at 20-28  d  of age  (Fig.  1).  The drop in 
systemic NO production and iNOS expression after day 17 
in  the  life  of TGF-[31 -/-  mice  suggests  that  mechanisms 
other than  TGF-[31  decrease  the  expression  of iNOS.  Al- 
though TGF-[31 may be the most potent negative regulator 
of NO  production  (5)  on the basis  of its  multiple  mecha- 
nisms of action in vitro (11, 22, 23), it is only one of a mul- 
titude  of agents  that  suppress  the  expression  of iNOS  in 
vitro:  the  cytokines  TGF-[32,  TGF-[33,  platelet-derived 
growth  factor,  fibroblast  growth factor,  epidermal  growth 
factor, insulin-like growth factor, and interleukins 4, 8, and 
10  (5);  endogenous  corticosteroids  (24);  N,N-dimethyl- 
arginine  (25);  thrombin  (26);  angiotensin  II  (27);  and  os- 
teopontin  (28).  It  is  unknown  whether  the  absence  of 
TGF-[31 leads to increased expression of any or all of these 
agents. 
The observation that systemic NO production is dramat- 
ically increased in TGF-[31-/-  mice suggested that this in- 
crease  was  in  some  way related  to  the  wasting  syndrome 
and death characteristic of these mice (6,  19). We therefore 
determined  whether  suppression  of NOS  enzyme activity 
would contribute to or correlate with an increase in the life 
span of these mice. We compared the serum levels of NO2 
and  NO3  of untreated  TGF-[31 -/-  mice  14--17  d  of age 
with  those  of mice  that  had  been  either  untreated  or 
treated  for ~-,1 wk with  t-NMA  (Fig.  2),  t-NAME  (data 
not shown),  or aminoguanidine  (data  not shown).  As can 
be seen in Fig. 2, 14--17-d-old TGF-[31 +/+ mice had 69  + 
13 ~zM NO2 plus NO3  (open bars; n =  12), and TGF-[31 +/- 
mice of similar age had 39  +  13 Ixm NO~  plus NO3  (gray 
bars;  n  =  6;  not  significantly  different  from  TGF-[31 +/+ 
mice).  In  contrast,  untreated  14-17-d-old  TGF-[31 -/- 
mice  (black  bars;  n  =  15)  had  290  -+  52  IxM  NO2  plus 
NO3  (P <0.005 vs.  TGF-[31 +/+ mice).  Serum NO~  plus 
NO3  levels  in  TGF-[31 -/-  mice  were  reduced  to  43  -+ 
19 txM NO2 plus NO3  (n =  3) after treatment for 8  +  1 d 
with L-NMA; Fig. 2, diagonally  hatched  bar,  14-18 d  of age; 
Figure 2.  Treatment  with L-NMA inhibits the elevated serum levels of 
NO 2 and NO3 in TGF-[31  -/- mice. TGF-131  +/+ mice (+/+; open bar, 
n =  12), TGF-131  +/- mice (+/-;graybar,  n = 6), TGF-131  -/- mice (-/-; 
black bar, n =  15), or TGF-[$1  -j- mice treated with t-NMA (-/-  + 
L-NMA; hatched bar, n =  3) were killed, and their serum levels of NO~ 
and NO 3 were determined. Single asterisk, P <0.005  when  compared 
with TGF-131  +/+ mice.  Double asterisk, P <0.001  when compared with 
TGF-[31-/-  mice. 
Figure 3.  The expression ofiNOS mRNA and protein is higher in the 
heart and kidneys ofTGF-I31  -/- mice  relative to TGF-I$1  §  littermates. 
Mice were sacrificed at the indicated ages, and the hearts (A and B) and 
kidneys (C and D) removed. The organs were processed for Northern 
blot analysis with a probe specific to iNOS or GAPDH as a control for 
loading (A and C) or immunoblot with anti-iNOS antibody (B and D). 
Migration of iNOS  produced by the mouse macrophage-like cell line 
RAW264.7  (data not shown) is indicated by the arrow. Experiment is 
representative of  three. 
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all competitive inhibitors of NOS activity (4), demonstrat- 
ing that the increased levels of NO2 and NO3 were due to 
aberrantly high NOS activity and not to another metabolic 
aberration.  Treatment with  these  agents  did not result in 
increased  life  span  of TGF-[31 -/-  mice,  but  long-term 
treatment with  a  glucocorticoid or rapamycin resulted in 
suppression of systemic NO production and was associated 
with increased hfe span of TGF-[31 -/- mice (Letterio, J.J., 
Y. Vodovotz, A.G.  Geiser, L.  Chesler, A.  Campbell,  and 
A.B. Roberts, manuscript in preparation). 
Our analysis of the age dependence of systemic NO pro- 
duction suggested that either iNOS expression or its activ- 
ity may be reduced by some mechanism in the days before 
the  death  of TGF-131 -/-  mice.  Homogenates from mice 
14-21  d  of age  showed  that  iNOS  mRNA  and  protein 
were expressed at their highest levels in the heart (Fig. 3, A 
and B, respectively) and kidney (Fig.  3,  C  and D, respec- 
tively) between days 15  and  17 in the life of TGF-[31 -/- 
mice, in parallel with serum NO2 and NO3 levels (Fig.  1). 
At later time points, however, iNOS protein expression in 
the heart and kidney ofTGF-[31  -/- mice decreased to levels 
almost indistinguishable  from those  of TGF-[31 +/+  htter- 
mates (data not shown). We next characterized the expres- 
sion of iNOS  protein at the cellular level by immunocy- 
tochemistry, iNOS  protein was  expressed at low levels in 
the medulla of TGF-[31+/+ mice (data not shown). We did 
not  find  significant  expression  of iNOS  in  glomeruli  of 
TGFq31 +/+ mice (Fig. 4 A). We found that the expression of 
iNOS protein was increased in the collecting ducts and tubu- 
lar epithelial cells, but not the glomeruli, of TGF-131 -/- mice 
relative to its expression in controls (Fig. 4; compare A and B). 
The increased expression of iNOS  mP,.NA  (Fig.  3  C) 
and protein (Fig.  3  D  and Fig. 4) in the kidney, an organ 
that is typically not inflamed in TGF-[M -/-  mice (6,  19), 
suggests that the increase in iNOS expression may not solely 
be  due  to  the  inflammatory infiltrate  observed in  TGF- 
131 -/- mice. Two mouse models of autoimmunity, that of 
experimental autoimmune encephalomyelitis (29) and that 
of the MRL-Ipr/lpr mouse (30),  are also associated with in- 
creased  systemic  NO  production.  Lowrance  et  al.  (31), 
however, have reported that MP,  L-Ipr/lpr mice have high 
circulating levels ofTGFq31, and thus the relation between 
an  autoimmune  phenotype  and  increased  systemic  NO 
production is not clear. 
Paradoxically, the increased systemic production of NO 
by TGF-[31 -/- mice may compensate partially for the lack 
of TGF-131  in  maintaining  normal lymphocyte prolifera- 
tion. Like TGF-[31 (2), NO can suppress  lymphocyte pro- 
liferation (32),  perhaps explaining the reduced proliferative 
responses  of lymphocytes  derived  from  14-d-old  TGF- 
131-/- mice as compared with controls (33).  Florquin et al. 
(21)  recently reported elevated systemic levels of NO in a 
model of shock induced by staphylococcal enterotoxin B. 
The role of NO in this system was to suppress  the prolifer- 
ation of T  lymphocytes: inhibition  of NO  production in 
mice undergoing shock increased morbidity owing to in- 
creased  T  lymphocyte proliferation  and  subsequent  pro- 
duction of TNF-ot (21). 
The increase in iNOS expression in TGF-131 -/- mice is 
most probably mediated indirectly via increases in the ex- 
pression of proinflammatory cytokines. Cytokines such as 
IFN-y, TNF-ot, IL-1, or IL-2 may induce iNOS  (4)  and 
are known to be regulated by TGF-131  (2). Shull et al. (19) 
have reported that TGF-[31 -/- mice exhibit increased ex- 
pression  of TNF-ot  and  IFN-~/  mlkNA,  but  not  IL-lix 
mP,  NA, as determined by PCP, analysis  of liver and lung 
tissues.  Christ et al. (33) have reported elevated IL-2 levels 
in the thymus of TGF-IM -/-  mice. However, a previous 
study from our laboratory suggested that the expression of 
IFN-~/ mRNA was not altered in TGF-[31 -/-  mice rela- 
tive to  its  expression in  controls  (8).  Future  studies  must 
determine  the  cellular and  organ  source of the  increased 
circulating levels of metabolites of NO, identify the mech- 
anisms  which  shut  off NO  production late  in  the  life of 
TGF-131 -/-  mice,  and  the  direct  physiological  conse- 
quences the increased production of  NO has on TGF-131-/- 
mice. 
Figure 4.  Expression  ofiNOS protein  is increased  in kidneys  from TGF-[31  -/- mice. Mice were sacrificed  at the indicated  age, and the kidneys  were 
removed and processed for immunocytochemistry  with anti-iNOS antibody. (A) Glomerulus from the kidney of a 15-d-old TGF-[31  +/§  mouse, 
￿  1,000. (B) Glomemlus  from the kidney  of a 15-d-old  TGF-~I1-/- mouse, ￿  1,000. Experiment  is representative  of  four. 
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